RIG-1 receptor expression in the pathology of Alzheimer's disease

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  De Rivero Vaccari, Juan P ^a   Brand III, Frank J ^a   Sedaghat, Christina ^a   Mash, Deborah C ^a   Dietrich, W D ^a   Keane, Robert W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Inflammation; Innate immunity; Mild cognitive impairment; Rig signaling; RLR

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; 5'PPP-RNA; AMYLOID BETA-PROTEIN (3-42), PYROGLUTAMYL(3)-; DDX58 PROTEIN, HUMAN; DEAD BOX PROTEIN; INTERFERON REGULATORY FACTOR 3; IRF3 PROTEIN, HUMAN; PEPTIDE FRAGMENT; VIRUS RNA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OCCIPITAL CORTEX; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TEMPORAL CORTEX; VERY ELDERLY; BLOOD; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; METABOLISM; OCCIPITAL LOBE; PATHOLOGY; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ASTROCYTES; CELLS, CULTURED; DEAD-BOX RNA HELICASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON REGULATORY FACTOR-3; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; OCCIPITAL LOBE; PEPTIDE FRAGMENTS; RNA, VIRAL; TEMPORAL LOBE;

EID: 84897957381     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-67     Document Type: Article

References (44)

1. Vollmar P, Kullmann JS, Thilo B, Claussen MC, Rothhammer V, Jacobi H, Sellner J, Nessler S, Korn T, Hemmer B. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. J Immunol 2010, 185:6338-6347. 10.4049/jimmunol.1001765, 20943998.
2. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010, 11:155-161. 10.1038/ni.1836, 2809046, 20037584.
3. Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, Siler DA, Markesbery WR, Arumugam TV, Mattson MP. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 2008, 213:114-121. 10.1016/j.expneurol.2008.05.014, 2597513, 18586243.
4. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2008, 5:23. 10.1186/1742-2094-5-23, 2430555, 18510752.
5. Minoretti P, Politi P, Coen E, Di Vito C, Bertona M, Bianchi M, Emanuele E. The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 2006, 397:159-163. 10.1016/j.neulet.2005.12.028, 16406317.
6. Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rube CE, Walter J, Heneka MT, Hartmann T, Menger MD, Fassbender K. TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. J Immunol 2012, 188:1098-1107. 10.4049/jimmunol.1101121, 22198949.
7. Wilkins C, Gale M. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010, 22:41-47. 10.1016/j.coi.2009.12.003, 3172156, 20061127.
8. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820. 10.1016/j.cell.2010.01.022, 20303872.
9. Taylor JM, Minter MR, Newman AG, Zhang M, Adlard PA, Crack PJ. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. Neurobiol Aging 2014, 35:1012-1023. 10.1016/j.neurobiolaging.2013.10.089, 24262201.
10. de Rivero Vaccari JP, Minkiewicz J, Wang X, De Rivero Vaccari JC, German R, Marcillo AE, Dietrich WD, Keane RW. Astrogliosis involves activation of retinoic acid-inducible gene-like signaling in the innate immune response after spinal cord injury. Glia 2012, 60:414-421. 10.1002/glia.22275, 3265608, 22161971.
11. Mawhinney LJ, de Vaccari Rivero JP, Dale GA, Keane RW, Bramlett HM. Heightened inflammasome activation is linked to age-related cognitive impairment in fischer 344 rats. BMC Neurosci 2011, 12:123. 10.1186/1471-2202-12-123, 3259063, 22133203.
12. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001, 58:397-405.
13. Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 2012, 123:13-30. 10.1007/s00401-011-0884-1, 3282485, 22101321.
14. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308. 10.1001/archneur.56.3.303, 10190820.
15. Fleming KC, Adams AC, Petersen RC. Dementia: diagnosis and evaluation. Mayo Clin Proc 1995, 70:1093-1107. 10.4065/70.11.1093, 7475341.
16. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD): part II standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486. 10.1212/WNL.41.4.479, 2011243.
17. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259. 10.1007/BF00308809, 1759558.
18. Schieb H, Kratzin H, Jahn O, Mobius W, Rabe S, Staufenbiel M, Wiltfang J, Klafki HW. Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. J Biol Chem 2011, 286:33747-33758. 10.1074/jbc.M111.246561, 3190810, 21795681.
19. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 5'-triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997. 10.1126/science.1132505, 17038590.
20. Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement 2011, 2011(7):208-244.
21. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 2008, 4:65-79. 10.1016/j.jalz.2007.10.001, 18631951.
22. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003, 60:1119-1122. 10.1001/archneur.60.8.1119, 12925369.
23. Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Vigo FS, Sommer B, Yankner BA. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci 2000, 3:460-464. 10.1038/74833, 10769385.
24. Yankner BA. New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. Nat Med 1996, 2:850-852. 10.1038/nm0896-850, 8705846.
25. Yankner BA. The pathogenesis of Alzheimer's disease: is amyloid beta-protein the beginning or the end?. Ann N Y Acad Sci 2000, 924:26-28.
26. Yankner BA, Lu T. Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 2009, 284:4755-4759. 10.1074/jbc.R800018200, 2643502, 18957434.
27. Ricci S, Fuso A, Ippoliti F, Businaro R. Stress-induced cytokines and neuronal dysfunction in Alzheimer's disease. J Alzheimers Dis 2012, 28:11-24.
28. Rogers J. Inflammation as a pathogenic mechanism in Alzheimer's disease. Arzneimittelforschung 1995, 45:439-442.
29. Rogers J. The inflammatory response in Alzheimer's disease. J Periodontol 2008, 79:1535-1543. 10.1902/jop.2008.080171, 18673008.
30. Rogers J, Shen Y. A perspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci 2000, 924:132-135.
31. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J Biol Chem 1999, 274:6421-6431. 10.1074/jbc.274.10.6421, 10037734.
32. Simard AR, Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry 2006, 11:327-335. 10.1038/sj.mp.4001809, 16491130.
33. Weninger SC, Yankner BA. Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nat Med 2001, 7:527-528. 10.1038/87839, 11329045.
34. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 2006, 9:271-276.
35. Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, Goux WJ, Lee V, Johnson GV, Webster SD, Cooper NR, Bradt B, Rogers J. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett 2001, 305:165-168. 10.1016/S0304-3940(01)01842-0, 11403931.
36. Lafon M, Megret F, Lafage M, Prehaud C. The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci 2006, 29:185-194. 10.1385/JMN:29:3:185, 17085778.
37. Malathi K, Paranjape JM, Bulanova E, Shim M, Guenther-Johnson JM, Faber PW, Eling TE, Williams BR, Silverman RH. A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L. Proc Natl Acad Sci USA 2005, 102:14533-14538. 10.1073/pnas.0507551102, 1239948, 16203993.
38. Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci USA 2009, 106:2770-2775. 10.1073/pnas.0807694106, 2650341, 19196953.
39. Rainer TH, Lam NY. Circulating nucleic acids and critical illness. Ann N Y Acad Sci 2006, 1075:271-277. 10.1196/annals.1368.035, 17108220.
40. Kitamura T, Kitamura M, Hino S, Tanaka N, Kurata K. Gender differences in clinical manifestations and outcomes among hospitalized patients with behavioral and psychological symptoms of dementia. J Clin Psychiatry 2012, 73:1548-1554. 10.4088/JCP.11m07614, 23290328.
41. Allaman I, Gavillet M, Belanger M, Laroche T, Viertl D, Lashuel HA, Magistretti PJ. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci 2010, 30:3326-3338. 10.1523/JNEUROSCI.5098-09.2010, 20203192.
42. Calvillo M, Diaz A, Limon DI, Mayoral MA, Chanez-Cardenas ME, Zenteno E, Montano LF, Guevara J, Espinosa B. Amyloid-beta induces a permanent phosphorylation of HSF-1, but a transitory and inflammation-independent overexpression of Hsp-70 in C6 astrocytoma cells. Neuropeptides 2013, 47:339-346. 10.1016/j.npep.2013.06.002, 23850171.
43. Grolla AA, Sim JA, Lim D, Rodriguez JJ, Genazzani AA, Verkhratsky A. Amyloid-beta and Alzheimer's disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions. Cell Death Dis 2013, 4:e623. 10.1038/cddis.2013.145, 3674354, 23661001.
44. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate a beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003, 971:197-209. 10.1016/S0006-8993(03)02361-8, 12706236.